TOPIGEN raises $26 million to accelerate clinical trials

Guest Contributor
September 19, 2007

Montreal-based TOPIGEN Pharmaceuticals Inc has secured $26 million in series C financing to accelerate Phase II clinical programs related to its lead products for respiratory therapeutics. The total raised to date from all sources is now $75 million and more may be added to the C series. Investors in the latest round are NovaQuest, MMV Financial Inc, BDC Venture Capital, Desjardins Venture Capital, Caisse de Depot et Placement du Quebec, T2C2/BIO 2000 and Lothian Partners 27. TOPIGEN therapeutics suppress pulmonary inflammation by delivering drugs directly to the site of cellular action in the lung through inhalation. Its two lead products target asthma and chronic obstructive pulmonary disease….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.